Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].

Clinical calcium - 1 Jan 2007

Nakanishi Shohei, Fukagawa Masafumi

Abstract excerpt

Calcimimetics drug such as cinacalcet suppress the secretion of parathyroid hormone by sensitizing parathyroid calcium receptors to extracellular ionized calcium. Standard treatment for secondary hyperparathyroidism is associated with the risk of hypercalcemia, but cinacalcet don't induce elevation of serum calcium. And some studies were reported the use of cinacalcet not only to manage primary...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Hyperparathyroidism, Primary
Share to Kidney Failure, Chronic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney Transplantation

Share to Naphthalenes

Share to Parathyroid Hormone

Share to Parathyroid Neoplasms

Share to Receptors, Calcium-Sensing

Source

Identifiers

PMID: 17211098
DOI: CliCa07018892

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].PMID 17211098Read ↗

[Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].Semantic proximity Read ↗

[Calcium receptor (CaR): a new approach to regulation of calcium homeostasis].Semantic proximity Read ↗

[Progress in diagnosis of and therapy for hypocalcemia: Differential diagnosis and classification of hypoparathyroidism].Semantic proximity Read ↗

[Bone and Nutrition. A prospect of calcium sensing receptor].Semantic proximity Read ↗

Hypercalcemia. Pathophysiological aspects.Semantic proximity Read ↗

[Progress in diagnosis and therapy: Hypocalcemia due to idiopathic hypoparathyroidism].Semantic proximity Read ↗

[Treatment of chronic hypocalcaemia during childhood].Semantic proximity Read ↗

Cinacalcet for management of hypercalcemia secondary to calcium-sensing receptor mutation.Semantic proximity Read ↗

The pharmacological profile and the clinical efficacy of the world's 1st intravenous calcimimetics; etelcalcetide hydrochloride (Parsabiv®).Semantic proximity Read ↗

[Hypercalcemia (with treatment)].Semantic proximity Read ↗

Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis.Semantic proximity Read ↗

[Physiopathology and therapy of familial hypocalciuric hypercalcemia].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.